Abstract
The ALPHEUS trial evaluated whether ticagrelor is more effective than clopidogrel in decreasing the risk of periprocedural myocardial necrosis in patients with stable coronary disease undergoing a very high-risk elective percutaneous coronary intervention (PCI). The clinical study documented that ticagrelor was not more effective than clopidogrel in this manner and did not cause an increase in severe bleeding, although it increased a risk of mild bleeding in 30 days after the coronary intervention.